Health Insurance Review and Assessment Policy Institute, Health Insurance Review and Assessment Service, Seoul, Republic of Korea.
Med Care. 2011 Apr;49(4):378-84. doi: 10.1097/MLR.0b013e31820292d1.
Medication adherence has been identified as a major factor influencing health outcomes in patients with type 2 diabetes.
We assessed the relationship between initial adherence to oral antihyperglycemic medications and subsequent health outcomes.
This was a retrospective cohort study of 40,082 patients enrolled in Korea's national health insurance program, who were 20 years of age or older and first diagnosed with type 2 diabetes in 2004. The patients were followed up for 3 years using claims data to measure adherence to oral antihyperglycemic medications for the initial 2 years after diagnosis and to investigate hospitalization, mortality, and healthcare costs in the third year of follow-up.
After adjusting for confounders, nonadherence in the first 2 years after prescription increased the risk for hospitalization in the third year compared with adherence over the same period [odds ratio (OR)=1.26, 95% confidence interval=1.08-1.47]. Nonadherence in at least one of the 2 years increased the risk for hospitalization compared with adherence in both years. In addition, nonadherence during both the first and second years was associated with statistically significantly greater risks for mortality during this period than was adherence (odds ratio=1.40, 95% confidence interval=1.01-1.95). Medication adherence decreased healthcare costs compared with nonadherence (β=-0.127; P<0.001).
Because improved medication adherence can produce better health outcomes for diabetes patients and also save national healthcare resources, government-sponsored healthcare policies to improve medication adherence among newly diagnosed diabetes patients are urgently required.
药物依从性已被确定为影响 2 型糖尿病患者健康结果的主要因素。
我们评估了初始口服抗高血糖药物依从性与后续健康结果之间的关系。
这是一项回顾性队列研究,纳入了参加韩国国家健康保险计划的 40082 例年龄在 20 岁及以上、2004 年首次被诊断为 2 型糖尿病的患者。使用索赔数据对患者进行了 3 年的随访,以测量诊断后最初 2 年内口服抗高血糖药物的依从性,并调查第 3 年的住院、死亡和医疗保健费用。
在校正混杂因素后,与同期依从性相比,处方后前 2 年内不依从增加了第 3 年住院的风险[比值比(OR)=1.26,95%置信区间(CI)=1.08-1.47]。至少有 1 年不依从的患者比 2 年均依从的患者发生住院的风险更高。此外,与 2 年均依从相比,第 1 年和第 2 年均不依从与该期间死亡率显著增加相关(OR=1.40,95%CI=1.01-1.95)。与不依从相比,药物依从性降低了医疗保健费用(β=-0.127;P<0.001)。
由于改善药物依从性可以为糖尿病患者带来更好的健康结果,还可以节省国家医疗保健资源,因此迫切需要政府发起的改善新诊断糖尿病患者药物依从性的医疗保健政策。